<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-0195</journal-id>
<journal-title><![CDATA[Revista mexicana de ciencias farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. cienc. farm]]></abbrev-journal-title>
<issn>1870-0195</issn>
<publisher>
<publisher-name><![CDATA[Asociación Farmacéutica Mexicana A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-01952015000200024</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio de liberación in vitro de ibuprofeno en grageas: influencia de la dosis y el aparato de disolución]]></article-title>
<article-title xml:lang="en"><![CDATA[In vitro release study of ibuprofen dragees: dose and dissolution apparatus influence]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina López]]></surname>
<given-names><![CDATA[José Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Lugo]]></surname>
<given-names><![CDATA[Carlos Abner]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hurtado y de la Peña]]></surname>
<given-names><![CDATA[Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Ramírez]]></surname>
<given-names><![CDATA[Adriana Miriam]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad Autónoma Metropolitana-Xochimilco Departamento Sistemas Biológicos ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2015</year>
</pub-date>
<volume>46</volume>
<numero>2</numero>
<fpage>24</fpage>
<lpage>32</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-01952015000200024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-01952015000200024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-01952015000200024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Con el objetivo de evaluar el efecto de la dosis y el sistema de disolución empleado en la liberación de ibuprofeno, a partir de medicamentos sólidos de liberación inmediata, se obtuvieron los perfiles de disolución del medicamento de referencia Motrin® (grageas de 400 y 600 mg) en los Aparatos 2 y 4 USP y a diferentes pHs. Con el Aparato 2 USP (50 rpm) a pH 6.8 únicamente el medicamento de 400 mg alcanzó el 85 % disuelto en 30 min. Se encontraron diferencias significativas en la eficiencia de disolución, atribuibles a la dosis y al aparato empleado (p&lt; 0.05). Los resultados sugieren la necesidad de reconsiderar los criterios de bioexención para medicamentos que contienen ibuprofeno.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: In order to evaluate the effect of the dose and the dissolution apparatus on the release of ibuprofen from immediate- release dosage forms, the dissolution profiles of reference product Motrin® (400 and 600 mg, dragees) in USP Apparatus 2 and 4 at different pHs, were obtained. Using USP Apparatus 2 at pH 6.8 only the 400 mg drug product reached the 85 % dissolved at 30 min. Significant differences in dissolution efficiency, related to dose and apparatus used, were found (p&lt; 0.05). The results suggest the need to reconsider biowaiver criteria for ibuprofen drug products.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ibuprofeno]]></kwd>
<kwd lng="es"><![CDATA[dosis]]></kwd>
<kwd lng="es"><![CDATA[celda de flujo continuo]]></kwd>
<kwd lng="es"><![CDATA[medicamento de referencia]]></kwd>
<kwd lng="en"><![CDATA[ibuprofen]]></kwd>
<kwd lng="en"><![CDATA[dose]]></kwd>
<kwd lng="en"><![CDATA[flow-through cell method]]></kwd>
<kwd lng="en"><![CDATA[reference product]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[Gilman]]></given-names>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2003</year>
<edition>10a</edition>
<page-range>697-717</page-range><publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindenberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koop]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dressman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pharm]]></source>
<year>2004</year>
<volume>58</volume>
<page-range>265-78</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A theorical basis for a biopharmaceutic drug classification the correlation of in vitro drug product dissolution and in vivo bioavailability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Lennernäs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Crison]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharm Res]]></source>
<year>1995</year>
<volume>12</volume>
<page-range>413-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>US Food and Drug Administration</collab>
<source><![CDATA[Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutic Classification System. CDER/FDA 2000]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biowaiver monographs for immediate release solid oral dosage forms ibuprofen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Potthast]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dressman]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Junginger]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Midha]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Oeser]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Vogelpoel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Barends]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Sci]]></source>
<year>2005</year>
<volume>94</volume>
<page-range>2121-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="confpro">
<source><![CDATA[USP 37/NF 32. 2014: United States Pharmacopeia. The National Formulary]]></source>
<year></year>
<conf-name><![CDATA[ U.S. Pharmacopeial Convention, Inc]]></conf-name>
<conf-loc>Rockville </conf-loc>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of dissolution profiles for albendazol tablets using USP apparatus 2 and 4]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Ramírez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Dev Ind Pharm]]></source>
<year>2003</year>
<volume>29</volume>
<page-range>777-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Disolución comparativa de indometacina en cápsulas utilizando los Aparatos 1 y 4 USP]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Ramírez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Mex Cienc Farm]]></source>
<year>2012</year>
<volume>43</volume>
<page-range>72-80</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow- through cell system]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Ramírez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Saudi Pharm J]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>141-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Investigation on the possibility of biowaivers for ibuprofen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Núñez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Torrado]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Potthast 31]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[García-Arieta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Sci]]></source>
<year>2011</year>
<volume>100</volume>
<page-range>2343-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of three dissolution apparatuses for testing calcium phosphate pellets used as ibuprofen delivery systems]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chevalier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Viana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Artaud]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chomette]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Haddouchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Devidts]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chulia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>597-605</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development and application of a biorelevant dissolution method using the USP apparatus 4 in early phase formulation development]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
<name>
<surname><![CDATA[Rawat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Flick]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[ZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cauchon]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[McElvain]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Pharm]]></source>
<year>2010</year>
<volume>7</volume>
<page-range>1466-77</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[In vitro evaluation of ibuprofen hot-melt extruded pellets employing different designs of flow through cell]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emara]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Abdelfattah]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Taha]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[El-Ashmawy]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Mursi]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm Pharm Sci]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>192-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The differences between the branded and generic medicines using solid dosage forms in-vitro dissolution testing]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Almeri]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Nayuni]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Anuil Akumar]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Perrett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Results Pharm Sci]]></source>
<year>2012</year>
<volume>2</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<source><![CDATA[Relación de Medicamentos de Referencia]]></source>
<year>2013</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of selected water-soluble excipients on the dissolution of paracetamol and ibuprofen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grattan]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Dev Ind Pharm]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>515-25</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<source><![CDATA[NOM-177-SSA1-2013, Norma Oficial Mexicana que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los Terceros Autorizados que realicen las pruebas de intercambiabilidad. Requisitos para realizar los estudios de biocomparabilidad. Requisitos a que deben sujetarse los Terceros Autorizados, Centros de Investigación o Instituciones Hospitalarias que realicen las pruebas de biocomparabilidad]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podczeck]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm]]></source>
<year>1993</year>
<volume>97</volume>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The concept of dissolution efficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Pharmacol]]></source>
<year>1975</year>
<volume>27</volume>
<page-range>48-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Establishment of sink conditions in dissolution rate determinations Theoretical considerations and application to non-disintegrating dosage forms]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gibaldi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Sci]]></source>
<year>1967</year>
<volume>56</volume>
<page-range>1238-42</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanism of sustained-action medication theoretical analysis of rate of release of solid drug dispersed in solid matrices]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Sci]]></source>
<year>1963</year>
<volume>52</volume>
<page-range>1145-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dependence of reaction velocity upon surface and agitation I. Theorical considerations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hixson]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Crowell]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<source><![CDATA[Ind Eng Chem]]></source>
<year>1931</year>
<volume>23</volume>
<page-range>923-31</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Linearization of dissolution rate curves by the Weibull function]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langenbucher]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Pharmacol]]></source>
<year>1972</year>
<volume>24</volume>
<page-range>979-81</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rawlings]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<source><![CDATA[Applied regression analysis: a research tool]]></source>
<year>1988</year>
<publisher-loc><![CDATA[Belmont CA ]]></publisher-loc>
<publisher-name><![CDATA[Wadsworth]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of dissolution profiles by ANOVA-based, model-dependent and-independent methods]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuksel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kanik]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Baykara]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm.]]></source>
<year>2000</year>
<volume>209</volume>
<page-range>57-67</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[DDSolver: an add-in program for modeling and comparison of drug dissolution profiles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Huo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[AAPS J.]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>263-71</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dissolution study of active pharmaceutical ingredients using the flow through apparatus USP 4]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beyssac]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lavigne]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Dissol Technol]]></source>
<year>2005</year>
<volume>12</volume>
<page-range>23-5</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[In vitro in vivo correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sunesen]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Müllertz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2005</year>
<volume>24</volume>
<page-range>305-13</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Standardized flow-cell method as an alternative to existing pharmacopoeial dissolution testing]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langenbucher]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Benz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kurth]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Moller]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Otz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharm Ind]]></source>
<year>1989</year>
<volume>51</volume>
<page-range>1276-81</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs ibuprofen and ketoprofen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsume]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Langguth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[García-Arieta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<source><![CDATA[Biopharm Drug Dis]]></source>
<year>2012</year>
<volume>33</volume>
<page-range>366-77</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Primidone-loaded poly-e-caprolactone nanocapsules incorporation efficiency and in vitro release profiles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferranti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Marchais]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chabenat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Orecchioni]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lafont]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm]]></source>
<year>1999</year>
<volume>193</volume>
<page-range>107-11</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lack of in vitro/in vivo correlations for 50 mg and 250 mg primidone tablets]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Straughn]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Mhatre]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Lesko]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharm Res]]></source>
<year>1998</year>
<volume>15</volume>
<page-range>1085-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dissolution testing for generic drugs an FDA perspective]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Davit]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<source><![CDATA[AAPS J]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>328-35</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The experience of implementing generic medicine policy in eight countries A review and recommendations for a successful promotion of generic medicine use]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassalin]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Alrasheedy]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[McLachlan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[AL-Tamimi]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed Ibrahim]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Aljadhey]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Saudi Pharm J]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>491-503</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
